{ "run": { "id": "cmnr13brb038gp658lh5qowv2", "region": "US", "assetId": "cmnr13bqt038cp658yndg3d4h", "ticker": "DGX", "snapshotId": "cmnr13br3038ep65899wzmivd", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:20:25.413Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr13br3038ep65899wzmivd", "assetId": "cmnr13bqt038cp658yndg3d4h", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 198.81, "dayLow": 194.05, "volume": 572808, "dayHigh": 198.89, "currency": "USD", "prevClose": 196.81, "week52Low": 157.2, "week52High": 213.5 }, "fundamentals": { "pe": 19.5636978579481, "beta": 0.37102265511486, "epsTTM": 8.87, "fcfTTM": 1226000000, "growth": { "epsYoy": 0.140102827763496, "revenueYoy": 0.1178079416531605 }, "sector": "Services-Medical Laboratories", "margins": { "net": 0.1516371728303486, "gross": 0.3849740383596482, "operating": 0.2088587474833104 }, "website": "https://questdiagnostics.com", "industry": "Health care", "pegRatio": 1.39638137004437, "ebitdaTTM": 1467000000, "forwardPe": 16.3707547169811, "marketCap": 20000000000, "totalCash": 420000000, "totalDebt": 6175000000, "debtEquity": 0.861227336122734, "quickRatio": 0.8024582967515365, "revenueTTM": 9437000000, "companyName": "QUEST DIAGNOSTICS INC", "priceToBook": 1.38107334910734, "currentRatio": 1.043898156277436, "dividendYield": 0.0185859806674651, "returnOnAssets": 0.08819722650231125, "returnOnEquity": 0.138354253835425, "analystOpinions": null, "businessSummary": "Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.", "enterpriseValue": 25016830000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 56000, "sharesOutstanding": 109866320, "enterpriseToEbitda": 17.05305385139741, "analystTargetMedian": null, "enterpriseToRevenue": 2.650930380417506, "operatingCashflowTTM": 1886000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:20:25.407Z" }, "results": [ { "id": "cmnr13bre038ip658az4dv17j", "runId": "cmnr13brb038gp658lh5qowv2", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"DGX\",\"currency\":\"USD\",\"current_price\":198.81,\"target_price_6m\":209,\"target_price_12m\":218,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Defensive low-beta healthcare services name with steady diagnostic demand\",\"Forward PE of ~16.4x implies meaningful EPS acceleration already discounted\",\"Revenue growth of ~12% YoY boosted by acquisitions and volume recovery\",\"Elevated net debt (~$5.75B) constrains capital return and acquisition flexibility\",\"Dividend yield of ~1.9% adds modest total return floor for patient holders\"],\"key_drivers\":[{\"driver\":\"Aging US population driving structural test volume growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"M&A integration (LifeLabs, other tuck-ins) boosting revenue\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Operating margin expansion toward 22%+ via lab automation\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Payer mix improvement and advanced diagnostics pricing\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Net debt of ~$5.75B limits financial flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Post-COVID base effect normalization pressuring comps\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Potential reimbursement rate cuts from CMS/PAMA reform\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Low beta (0.37) provides portfolio stability in volatile markets\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"CMS reimbursement cuts under PAMA could compress margins materially\",\"Integration risk from recent acquisitions diluting returns on capital\",\"Rising competition from hospital outreach programs and at-home testing\",\"Macro slowdown reducing employer-sponsored screening volumes\",\"Leverage ratio limits buyback capacity if earnings disappoint\"],\"assumptions\":{\"revenue_cagr_3y\":0.065,\"ebit_margin_target\":0.22,\"wacc\":0.08,\"terminal_multiple\":16},\"scenarios\":{\"bear\":{\"target_price\":175,\"prob\":0.2,\"notes\":\"Reimbursement cuts and acquisition missteps compress multiples to ~14x forward earnings.\"},\"base\":{\"target_price\":218,\"prob\":0.55,\"notes\":\"Steady organic growth plus margin expansion supports ~17x forward EPS of ~$12.80.\"},\"bull\":{\"target_price\":245,\"prob\":0.25,\"notes\":\"Successful integration and advanced diagnostics mix push EPS above $13.50 at 18x multiple.\"}},\"method_notes\":\"Blended forward PE and EV/EBITDA approach. Forward EPS estimated at ~$12.80 base case (snapshot forward PE implies ~$12.14 current consensus, grown modestly). Applied 17x PE for base, cross-checked with EV/EBITDA ~16x on ~$1.55B EBITDA. 12M target of $218 implies ~9.7% price return + ~1.9% dividend = ~11.5% total return, consistent with BUY. Confidence moderate due to near-52wk-high entry and debt load. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "ai-equity-research-v1", "risks": [ "CMS reimbursement cuts under PAMA could compress margins materially", "Integration risk from recent acquisitions diluting returns on capital", "Rising competition from hospital outreach programs and at-home testing", "Macro slowdown reducing employer-sponsored screening volumes", "Leverage ratio limits buyback capacity if earnings disappoint" ], "ticker": "DGX", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady organic growth plus margin expansion supports ~17x forward EPS of ~$12.80.", "target_price": 218 }, "bear": { "prob": 0.2, "notes": "Reimbursement cuts and acquisition missteps compress multiples to ~14x forward earnings.", "target_price": 175 }, "bull": { "prob": 0.25, "notes": "Successful integration and advanced diagnostics mix push EPS above $13.50 at 18x multiple.", "target_price": 245 } }, "confidence": 0.62, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.065, "terminal_multiple": 16, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Aging US population driving structural test volume growth", "impact": "HIGH", "direction": "POS" }, { "driver": "M&A integration (LifeLabs, other tuck-ins) boosting revenue", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating margin expansion toward 22%+ via lab automation", "impact": "MED", "direction": "POS" }, { "driver": "Payer mix improvement and advanced diagnostics pricing", "impact": "MED", "direction": "POS" }, { "driver": "Net debt of ~$5.75B limits financial flexibility", "impact": "MED", "direction": "NEG" }, { "driver": "Post-COVID base effect normalization pressuring comps", "impact": "MED", "direction": "NEG" }, { "driver": "Potential reimbursement rate cuts from CMS/PAMA reform", "impact": "HIGH", "direction": "NEG" }, { "driver": "Low beta (0.37) provides portfolio stability in volatile markets", "impact": "LOW", "direction": "POS" } ], "method_notes": "Blended forward PE and EV/EBITDA approach. Forward EPS estimated at ~$12.80 base case (snapshot forward PE implies ~$12.14 current consensus, grown modestly). Applied 17x PE for base, cross-checked with EV/EBITDA ~16x on ~$1.55B EBITDA. 12M target of $218 implies ~9.7% price return + ~1.9% dividend = ~11.5% total return, consistent with BUY. Confidence moderate due to near-52wk-high entry and debt load. Not investment advice.", "current_price": 198.81, "recommendation": "BUY", "thesis_bullets": [ "Defensive low-beta healthcare services name with steady diagnostic demand", "Forward PE of ~16.4x implies meaningful EPS acceleration already discounted", "Revenue growth of ~12% YoY boosted by acquisitions and volume recovery", "Elevated net debt (~$5.75B) constrains capital return and acquisition flexibility", "Dividend yield of ~1.9% adds modest total return floor for patient holders" ], "target_price_6m": 209, "target_price_12m": 218 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 45515, "createdAt": "2026-04-09T05:20:25.413Z", "usage": { "inputTokens": 3568, "outputTokens": 1680, "costUsd": 0.05984 } }, { "id": "cmnr13bre038lp658n3z9iune", "runId": "cmnr13brb038gp658lh5qowv2", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Equity Research AI v1.0\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"DGX\",\n \"currency\": \"USD\",\n \"current_price\": 198.81,\n \"target_price_6m\": 205.0,\n \"target_price_12m\": 215.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Steady revenue growth from healthcare demand.\",\n \"Strong operating margins enhance profitability.\",\n \"Manageable debt with consistent cash flows.\",\n \"Opportunities in industry consolidation.\",\n \"Risks from regulation and competition.\"\n ],\n \"key_drivers\": [\n {\"driver\": \"Healthcare demand growth\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Operational efficiency\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Debt levels\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"Regulatory environment\", \"impact\": \"HIGH\", \"direction\": \"NEG\"},\n {\"driver\": \"Technological advancements\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Competitive landscape\", \"impact\": \"MED\", \"direction\": \"NEG\"}\n ],\n \"risks\": [\n \"Regulatory changes affecting reimbursements\",\n \"Economic slowdown reducing patient volumes\",\n \"Increased competition pressuring margins\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.08,\n \"ebit_margin_target\": 0.2,\n \"wacc\": 0.08,\n \"terminal_multiple\": 16.0\n },\n \"scenarios\": {\n \"bear\": {\"target_price\": 180.0, \"prob\": 0.2, \"notes\": \"Slow growth and multiple contraction.\"},\n \"base\": {\"target_price\": 215.0, \"prob\": 0.6, \"notes\": \"Steady earnings growth with stable multiple.\"},\n \"bull\": {\"target_price\": 240.0, \"prob\": 0.2, \"notes\": \"Accelerated growth and multiple expansion.\"}\n },\n \"method_notes\": \"DCF valuation with 8% EPS growth and 16x terminal P/E. BUY due to 8% expected return. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "Equity Research AI v1.0", "risks": [ "Regulatory changes affecting reimbursements", "Economic slowdown reducing patient volumes", "Increased competition pressuring margins" ], "ticker": "DGX", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady earnings growth with stable multiple.", "target_price": 215 }, "bear": { "prob": 0.2, "notes": "Slow growth and multiple contraction.", "target_price": 180 }, "bull": { "prob": 0.2, "notes": "Accelerated growth and multiple expansion.", "target_price": 240 } }, "confidence": 0.65, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.08, "terminal_multiple": 16, "ebit_margin_target": 0.2 }, "key_drivers": [ { "driver": "Healthcare demand growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Operational efficiency", "impact": "MED", "direction": "POS" }, { "driver": "Debt levels", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory environment", "impact": "HIGH", "direction": "NEG" }, { "driver": "Technological advancements", "impact": "HIGH", "direction": "POS" }, { "driver": "Competitive landscape", "impact": "MED", "direction": "NEG" } ], "method_notes": "DCF valuation with 8% EPS growth and 16x terminal P/E. BUY due to 8% expected return. Not investment advice.", "current_price": 198.81, "recommendation": "BUY", "thesis_bullets": [ "Steady revenue growth from healthcare demand.", "Strong operating margins enhance profitability.", "Manageable debt with consistent cash flows.", "Opportunities in industry consolidation.", "Risks from regulation and competition." ], "target_price_6m": 205, "target_price_12m": 215 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 334, "createdAt": "2026-04-09T05:20:25.413Z", "usage": { "inputTokens": 2081, "outputTokens": 3872, "costUsd": 0.002209 } }, { "id": "cmnr13bre038jp658eb6ns9d7", "runId": "cmnr13brb038gp658lh5qowv2", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch-Alpha-v1\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"DGX\",\n \"currency\": \"USD\",\n \"current_price\": 198.81,\n \"target_price_6m\": 208.00,\n \"target_price_12m\": 218.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.80,\n \"thesis_bullets\": [\n \"Defensive healthcare play with low beta (0.37) and consistent free cash flow generation.\",\n \"Base testing volumes show resilient growth, offsetting pandemic-era revenue declines.\",\n \"Tuck-in M&A strategy expands hospital outreach and regional market share effectively.\",\n \"Advanced diagnostics and genetic testing provide higher-margin growth opportunities.\",\n \"Valuation at 16.4x forward P/E is reasonable given mid-teens EPS growth trajectory.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Base testing volume growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Medicare reimbursement (PAMA) cuts\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Hospital outreach M&A\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Advanced diagnostics expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Labor and wage inflation\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Automation and AI efficiencies\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Further Medicare reimbursement cuts under PAMA.\",\n \"Increased hospital insourcing of clinical lab testing.\",\n \"Persistent wage inflation compressing operating margins.\",\n \"Regulatory scrutiny on lab-developed tests (LDTs).\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.055,\n \"ebit_margin_target\": 0.215,\n \"wacc\": 0.075,\n \"terminal_multiple\": 16.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 175.00,\n \"prob\": 0.20,\n \"notes\": \"Reimbursement cuts and wage inflation severely compress margins.\"\n },\n \"base\": {\n \"target_price\": 218.00,\n \"prob\": 0.60,\n \"notes\": \"Steady volume growth and accretive M&A drive mid-single-digit revenue growth.\"\n },\n \"bull\": {\n \"target_price\": 245.00,\n \"prob\": 0.20,\n \"notes\": \"Advanced diagnostics outpace expectations, driving significant multiple expansion.\"\n }\n },\n \"method_notes\": \"Valuation based on a blend of 16.5x forward P/E and DCF (7.5% WACC). Target implies ~10% upside, supporting a BUY rating. This is not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "EquityResearch-Alpha-v1", "risks": [ "Further Medicare reimbursement cuts under PAMA.", "Increased hospital insourcing of clinical lab testing.", "Persistent wage inflation compressing operating margins.", "Regulatory scrutiny on lab-developed tests (LDTs)." ], "ticker": "DGX", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady volume growth and accretive M&A drive mid-single-digit revenue growth.", "target_price": 218 }, "bear": { "prob": 0.2, "notes": "Reimbursement cuts and wage inflation severely compress margins.", "target_price": 175 }, "bull": { "prob": 0.2, "notes": "Advanced diagnostics outpace expectations, driving significant multiple expansion.", "target_price": 245 } }, "confidence": 0.8, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.055, "terminal_multiple": 16.5, "ebit_margin_target": 0.215 }, "key_drivers": [ { "driver": "Base testing volume growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Medicare reimbursement (PAMA) cuts", "impact": "HIGH", "direction": "NEG" }, { "driver": "Hospital outreach M&A", "impact": "MED", "direction": "POS" }, { "driver": "Advanced diagnostics expansion", "impact": "MED", "direction": "POS" }, { "driver": "Labor and wage inflation", "impact": "MED", "direction": "NEG" }, { "driver": "Automation and AI efficiencies", "impact": "LOW", "direction": "POS" } ], "method_notes": "Valuation based on a blend of 16.5x forward P/E and DCF (7.5% WACC). Target implies ~10% upside, supporting a BUY rating. This is not investment advice.", "current_price": 198.81, "recommendation": "BUY", "thesis_bullets": [ "Defensive healthcare play with low beta (0.37) and consistent free cash flow generation.", "Base testing volumes show resilient growth, offsetting pandemic-era revenue declines.", "Tuck-in M&A strategy expands hospital outreach and regional market share effectively.", "Advanced diagnostics and genetic testing provide higher-margin growth opportunities.", "Valuation at 16.4x forward P/E is reasonable given mid-teens EPS growth trajectory." ], "target_price_6m": 208, "target_price_12m": 218 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 26185, "createdAt": "2026-04-09T05:20:25.413Z", "usage": { "inputTokens": 2440, "outputTokens": 820, "costUsd": 0.01472 } }, { "id": "cmnr13bre038hp658nivxj3w7", "runId": "cmnr13brb038gp658lh5qowv2", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"gpt-5\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"DGX\",\"currency\":\"USD\",\"current_price\":198.81,\"target_price_6m\":206,\"target_price_12m\":213,\"recommendation\":\"BUY\",\"confidence\":0.63,\"thesis_bullets\":[\"Defensive diagnostics demand supports resilient cash flow and low-beta downside protection.\",\"Forward P/E near 16x looks reasonable for double-digit EPS growth.\",\"Strong operating margins and $1.2B FCF support dividends, buybacks, and debt service.\",\"Hospital partnerships and advanced testing can offset routine testing price pressure.\",\"Debt load and reimbursement/labor risk cap upside, keeping return outlook moderate.\"],\"key_drivers\":[{\"driver\":\"Routine test volume growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Advanced diagnostics mix\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Hospital outreach expansion\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Margin discipline\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Debt reduction from FCF\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Reimbursement pressure\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Labor cost inflation\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Acquisition integration\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Medicare/commercial reimbursement cuts\",\"Volume normalization after episodic testing tailwinds\",\"Labor and logistics inflation\",\"Leverage limits capital allocation flexibility\",\"Regulatory or compliance setbacks\"],\"assumptions\":{\"revenue_cagr_3y\":4.5,\"ebit_margin_target\":20,\"wacc\":7.7,\"terminal_multiple\":14.5},\"scenarios\":{\"bear\":{\"target_price\":180,\"prob\":0.2,\"notes\":\"Reimbursement cuts and softer volumes compress margins.\"},\"base\":{\"target_price\":213,\"prob\":0.55,\"notes\":\"Steady core volumes and stable margins support modest rerating.\"},\"bull\":{\"target_price\":236,\"prob\":0.25,\"notes\":\"Advanced testing and hospital wins drive faster earnings growth.\"}},\"method_notes\":\"Used snapshot quote/fundamentals as authoritative. 12M target blends forward earnings and EV/EBIT valuation on 4.5% 3Y revenue CAGR and ~20% EBIT margin, with scenarios for reimbursement and cost pressure. No sell-side targets used; snapshot values override any external conflicts. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "gpt-5", "risks": [ "Medicare/commercial reimbursement cuts", "Volume normalization after episodic testing tailwinds", "Labor and logistics inflation", "Leverage limits capital allocation flexibility", "Regulatory or compliance setbacks" ], "ticker": "DGX", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady core volumes and stable margins support modest rerating.", "target_price": 213 }, "bear": { "prob": 0.2, "notes": "Reimbursement cuts and softer volumes compress margins.", "target_price": 180 }, "bull": { "prob": 0.25, "notes": "Advanced testing and hospital wins drive faster earnings growth.", "target_price": 236 } }, "confidence": 0.63, "assumptions": { "wacc": 7.7, "revenue_cagr_3y": 4.5, "terminal_multiple": 14.5, "ebit_margin_target": 20 }, "key_drivers": [ { "driver": "Routine test volume growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Advanced diagnostics mix", "impact": "MED", "direction": "POS" }, { "driver": "Hospital outreach expansion", "impact": "MED", "direction": "POS" }, { "driver": "Margin discipline", "impact": "HIGH", "direction": "POS" }, { "driver": "Debt reduction from FCF", "impact": "MED", "direction": "POS" }, { "driver": "Reimbursement pressure", "impact": "HIGH", "direction": "NEG" }, { "driver": "Labor cost inflation", "impact": "MED", "direction": "NEG" }, { "driver": "Acquisition integration", "impact": "LOW", "direction": "POS" } ], "method_notes": "Used snapshot quote/fundamentals as authoritative. 12M target blends forward earnings and EV/EBIT valuation on 4.5% 3Y revenue CAGR and ~20% EBIT margin, with scenarios for reimbursement and cost pressure. No sell-side targets used; snapshot values override any external conflicts. not investment advice", "current_price": 198.81, "recommendation": "BUY", "thesis_bullets": [ "Defensive diagnostics demand supports resilient cash flow and low-beta downside protection.", "Forward P/E near 16x looks reasonable for double-digit EPS growth.", "Strong operating margins and $1.2B FCF support dividends, buybacks, and debt service.", "Hospital partnerships and advanced testing can offset routine testing price pressure.", "Debt load and reimbursement/labor risk cap upside, keeping return outlook moderate." ], "target_price_6m": 206, "target_price_12m": 213 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_05bb51e9bb6f88a00069d75817a25c8190b474b050e5b0e022", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 41934, "createdAt": "2026-04-09T05:20:25.413Z", "usage": { "inputTokens": 2353, "outputTokens": 2448, "costUsd": 0.03839 } }, { "id": "cmnr13bre038kp658t72fpi61", "runId": "cmnr13brb038gp658lh5qowv2", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI DCF Valuation Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"DGX\",\n \"currency\": \"USD\",\n \"current_price\": 198.81,\n \"target_price_6m\": 212,\n \"target_price_12m\": 225,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Steady revenue growth from test volumes and acquisitions\",\n \"Improving margins through cost optimization initiatives\",\n \"Low beta offers portfolio diversification benefits\",\n \"High debt load poses risk in higher interest environment\",\n \"Fair valuation with moderate upside to base case\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Test volume growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Acquisition synergies\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Reimbursement rate pressures\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Operational efficiency gains\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Debt servicing costs\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Innovation in esoteric testing\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Industry consolidation\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Regulatory changes in lab reimbursements\",\n \"Increased competition from hospitals\",\n \"Failure to integrate acquisitions\",\n \"Rising interest expenses on debt\",\n \"Economic slowdown in testing demand\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.07,\n \"ebit_margin_target\": 0.22,\n \"wacc\": 0.08,\n \"terminal_multiple\": 15\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 175,\n \"prob\": 0.25,\n \"notes\": \"Persistent pricing pressure and lower volumes erode margins.\"\n },\n \"base\": {\n \"target_price\": 225,\n \"prob\": 0.5,\n \"notes\": \"Moderate growth and margin improvement align with expectations.\"\n },\n \"bull\": {\n \"target_price\": 265,\n \"prob\": 0.25,\n \"notes\": \"Accelerated innovation and market share gains boost performance.\"\n }\n },\n \"method_notes\": \"DCF using 7% revenue CAGR, 22% EBIT margin, 8% WACC and 15x terminal multiple. Balanced bull/bear factors yield modest upside. not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI DCF Valuation Model", "risks": [ "Regulatory changes in lab reimbursements", "Increased competition from hospitals", "Failure to integrate acquisitions", "Rising interest expenses on debt", "Economic slowdown in testing demand" ], "ticker": "DGX", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Moderate growth and margin improvement align with expectations.", "target_price": 225 }, "bear": { "prob": 0.25, "notes": "Persistent pricing pressure and lower volumes erode margins.", "target_price": 175 }, "bull": { "prob": 0.25, "notes": "Accelerated innovation and market share gains boost performance.", "target_price": 265 } }, "confidence": 0.62, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.07, "terminal_multiple": 15, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Test volume growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Acquisition synergies", "impact": "MED", "direction": "POS" }, { "driver": "Reimbursement rate pressures", "impact": "HIGH", "direction": "NEG" }, { "driver": "Operational efficiency gains", "impact": "MED", "direction": "POS" }, { "driver": "Debt servicing costs", "impact": "MED", "direction": "NEG" }, { "driver": "Innovation in esoteric testing", "impact": "MED", "direction": "POS" }, { "driver": "Industry consolidation", "impact": "LOW", "direction": "POS" } ], "method_notes": "DCF using 7% revenue CAGR, 22% EBIT margin, 8% WACC and 15x terminal multiple. Balanced bull/bear factors yield modest upside. not investment advice.", "current_price": 198.81, "recommendation": "BUY", "thesis_bullets": [ "Steady revenue growth from test volumes and acquisitions", "Improving margins through cost optimization initiatives", "Low beta offers portfolio diversification benefits", "High debt load poses risk in higher interest environment", "Fair valuation with moderate upside to base case" ], "target_price_6m": 212, "target_price_12m": 225 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "599950c5-3f38-94a8-b836-ec996a2ecc86", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 15810, "createdAt": "2026-04-09T05:20:25.413Z", "usage": { "inputTokens": 2692, "outputTokens": 3247, "costUsd": 0.056781 } } ] } }